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Available online 18 August 2016Objective: The online PatientsLikeMe®Epilepsy Community allows patientswith epilepsy to record,monitor, and
share their demographic, disease, and treatment characteristics, providing valuable insights into patient
perceptions and understanding of epilepsy. The objective of this retrospective analysis was to characterize the
proﬁle of users and their disease and identify factors predictive of poor health-related quality of life (HRQoL),
while assessing the platform's potential in providing patient-reported data for research purposes.
Methods: Data recorded (January 2010–November 2011) by Epilepsy Community members, with an epilepsy
diagnosis and who reported N1 seizure, included the following: sociodemographic and disease characteristics,
treatments, symptoms, side effects perceived as medication-related, seizure occurrence, and standardized
questionnaires (Quality of Life in Epilepsy Inventory [QOLIE-31/P], EuroQoL 5-Dimensions Scale, 3 Levels
[EQ-5D-3L], and Hospital Anxiety and Depression Scale [HADS]). Univariate andmultivariate logistic regressions
were conducted to identify predictors of poor HRQoL.
Results:During the study period, the Epilepsy Community comprised 3073 patients, of whom 71.5%were female,
had a mean age of 37.8 years, and had a mean epilepsy duration of 17.7 years. The most frequently reported
moderate/severe symptoms (n = 2135) included memory problems (60.2%), problems concentrating (53.8%),
and fatigue (50.0%). Medication-related side effects (n = 639) included somnolence (23.2%), fatigue (17.2%),
and memory impairment (13.8%). The QOLIE-31/P scores (n = 1121) were signiﬁcantly worse in patients who
experienced a recent seizure. For QOLIE-31/P, highly predictive factors for poor HRQoL included the following:
mild/moderate problems concentrating, depression, memory problems, treatment side effects, occurrence of
tonic–clonic seizures, and epilepsy duration ≤1 year. For EQ-5D-3L, highly predictive factors for poor HRQoL
included the following: pain, depression, and comorbidities. Patients on newer AEDs were less likely to report
poor HRQoL (QOLIE-31/P).
Signiﬁcance: These ﬁndings move further towards supporting the feasibility and usefulness of collecting real-
world, anonymized data recorded by patients online. The data provide insights into factors impacting HRQoL,
suggesting that a holistic treatment approach beyond seizure control should be considered in epilepsy.
© 2016 UCB,Brussels,Belgium. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Health-related quality of life (HRQoL) describes an individual's self-
perception of well-being, which includes physical, mental, emotional,
and social domains of life [1,2]; HRQoL focuses on the impact health
status has on quality of life. In epilepsy, the occurrence of seizures has
a negative impact on the HRQoL of those living with epilepsy [3], with
higher seizure frequency and severity resulting in decreased patient
HRQoL [4]. Other factors also contribute to poor HRQoL among patients
with epilepsy, such as the occurrence of side effects associated withcle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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such as depression and anxiety [3,6]; the perceived stigma of
epilepsy [7]; and a reduced level of independence (e.g., not being
able to drive) [8]. Improving the HRQoL of patients with epilepsy is
an important component of contemporary disease management
strategies [9], in addition to treating or preventing the occurrence
of seizures.
Disease management and patient support strategies have evolved
signiﬁcantly over the past decade, with many patients now taking a
more active role in collaboratingwith their healthcare provider(s) [10,11].
The popularity of networking sites, online communities, and virtual
forums, where patients can discuss their health concerns and exchange
information, is growing, especially for those living with chronic diseases
[11]. PatientsLikeMe® (http://www.patientslikeme.com) is an online
health data-sharing platform for patients with life-changing diseases.
The main goals of the website are to provide patients with the tools to
record, track, and share their disease characteristics and outcomes; to
help patients learn how to improve their care through peer-to-peer
interactions; and to enhance understanding of how the disease and its
treatment can potentially impact their lives [10,11]. The PatientsLikeMe
Epilepsy Community, launched in the United States in January 2010,
was developed in partnership with UCB Pharma. The perceived beneﬁts
reported by patients using the system include the ability to connect
with others experiencing the same symptoms, having a better under-
standing of their seizures, learningmore about symptoms or treatments
[11], and improvement in patient self-management and self-efﬁcacy
[12].
Through this research, data collected from PatientsLikeMe Epilepsy
Community members were utilized to help characterize demographic
and epilepsy characteristics in this patient population, including
symptoms and medication-related side effects, and to identify factors
predictive of poor HRQoL. In addition, the potential of the platform for
collecting patient-reported data suitable for research purposes was
assessed, as were the validated and standardized instruments used to
record HRQoL-related data from patients with epilepsy.
2. Methods
2.1. Study population
PatientsLikeMe Epilepsy Communitymembers,who logged in to the
website between January 2010 and November 2011, reported a diagno-
sis of epilepsy, and had experienced more than one seizure during their
lifetime, were included in the analysis. Initially, the community was
only accessible to users in the United States; however, from April
2011, it became available worldwide (English language only). Members
and users of the site became aware of the opportunity to join
PatientsLikeMe through online advertising (e.g., on Google and
Facebook), media partnerships, press coverage, word of mouth, and
physician referral.
All members of the PatientsLikeMe Epilepsy Community agreed to
be contacted for research as a condition of joining the community and
were free to opt in or out, allowing for them to only disclose information
they were willing to share. It was made clear that there would be no
adverse consequences if members elected not to participate.
Institutional review board approval was not sought because of the
noninterventional nature of the analysis.
2.2. Data collection
Patients (or their caregiver [parent or guardian])were able to record
information on sociodemographic characteristics and a range of
epilepsy and treatment-related characteristics. Patients could record the
occurrence and severity of symptoms (none, mild, moderate, severe)
using a predeﬁned checklist (Supplementary Fig. 1A). The symptom
checklist was developed by a panel of epilepsy experts and includedsymptoms considered likely to occur frequently among patients with
epilepsy (anxiety, depression, fatigue, headache, insomnia, memory
problems, pain, problems concentrating, and somnolence). Patients
could also document their treatment history and current treatment(s)
and specify any side effects they perceived to be related to their
treatment (medication-related side effects; assessed as mild, moderate,
or severe) (Supplementary Fig. 1B). Side effects were not prespeciﬁed.
However, a drop-down box listing side effects previously reported by
users of the PatientsLikeMe site was available and appeared once the
user began typing in his/her side effects. The user could also include
verbatim side effects where applicable. Side-effect terms were classiﬁed
according to the Medical Dictionary for Regulatory Activities coding
[13] version 14.1. In line with adverse event reporting regulations, a
pharmacovigilance system was employed during the data collection
period to identify, record, evaluate, and report medication-related side
effects attributed to UCB products.
Patients also had the opportunity to complete and review their
information for a number of validated, standardized patient-reported
outcome (PRO) instruments, namely, the Quality of Life in Epilepsy In-
ventory (QOLIE-31/P) [14], the Hospital Anxiety and Depression Scale
(HADS) [15], and the EuroQoL 5-Dimensions Scale, 3 Levels (EQ-5D-3L)
[16]. These instruments were selected as QOLIE-31/P is the most widely
used assessment of HRQoL in epilepsy trials, HADS captures varying
levels of anxiety and depression and iswidely referenced in the literature,
and the EQ-5D-3L is inwidespread use for health technology assessments
by agencies such as the National Institute for Health and Care Excellence
(NICE). The QOLIE-31/P is an epilepsy-speciﬁc HRQoL instrument, which
comprises 30 items grouped into seven multi-item subscales, assessing
seizure worry, overall quality of life, emotional well-being, energy/
fatigue, cognitive function, medication effects, and social function. It re-
quests that participants take into consideration the last 4 weeks when
responding. It also includes an additional, overall health status item
[14,17] not included in the total score calculation. The QOLIE-31/P total
score is calculated as a weighted average of the subscale scores and
ranges from 0 to 100, with 100 representing the best HRQoL [14,17].
The HADS instrument assesses the presence and severity of anxiety and
depression and requests that the previous week be considered when
responding. It consists of 14 items, scored on a 4-point severity scale.
An anxiety score and a depression score are calculated, each ranging
from 0 to 21, with levels of anxiety and depression classiﬁed as follows:
normal (0–7), mild (8–10), moderate (11–14), and severe (15–21)
[15]. The EQ-5D-3L is a generic instrument assessing health status that
enables comparisonwith other diseases [16]. It includes ﬁve items cover-
ing key dimensions of life, including the following: mobility, self-care,
usual activities, pain/discomfort, and anxiety/depression, which are
rated as follows: no problem, some/moderate problems, or extreme
problems [16]. These dimensions are used to determine the patient's
health state, which is mapped to a utility score anchored at 0 and 1,
with 1 representing full health [16]. The overall health status item is
measured on a visual analog scale from 0 to 100, with 100 representing
full health. The EQ-5D-3L instrument requests that participants take
into consideration ‘your own health state today’ when responding. The
EQ-5D-3L utility score was calculated using US weights taken from the
general population [18].
Patientswere able to update their proﬁle at any time andwere asked
to complete the battery of PRO instruments at least once. Before the
completion of the PRO instruments, patients were prompted to update
their proﬁle and were required to provide information about their sei-
zure experience during the last 4 weeks (experience/no experience of
simple partial, complex partial, or generalized tonic–clonic seizure).
The PRO instruments were provided in the following order: QOLIE-31/
P, HADS, and EQ-5D, and all questions per page had to be answered in
order to progress to the next page or to the next PRO instrument. Data
were collected from theﬁrst completion of each of the PRO instruments.
The results of the PRO instruments completed by each patient were
available for the patient to view personally on the PatientsLikeMe
22 C. de la Loge et al. / Epilepsy & Behavior 63 (2016) 20–28website, as well as being compiled anonymously with other patients'
data.
For a further understanding of the interface of the PatientsLikeMe
site, Wicks et al. (2012) [11] could be consulted.
2.3. Analysis
All datawere anonymized and retrospectively analyzed. The popula-
tion with epilepsy was deﬁned as all patients who recorded a diagnosis
of epilepsy and more than one seizure during their lifetime. Patients
from the population with epilepsy who had also completed the
predeﬁned symptom checklist at least once comprised the population
with symptoms, and those who also completed the PRO instruments
at least once comprised the PRO population. The population with side
effects comprised those patients from the population with epilepsy
who also recorded at least one medication-related side effect.
The demographic and epilepsy characteristics recorded at the time of
ﬁrst completion of the online assessmentswere summarized descriptive-
ly. Similarly, descriptive analysis of current symptoms data, including
symptom severity and HRQoL, utilized data recorded by each patient at
ﬁrst completion.
To determine the association between the occurrence of seizures
and HRQoL, PRO scores were compared between subgroups of patients
who had or had not experienced seizures within the preceding 4 weeks
before the assessment (no seizures, ≥1 generalized tonic–clonic seizure
[GTC, which included primary or secondarily generalized tonic–clonic
seizures], ≥1 non-GTC seizure [which included any seizure not classiﬁed
as a GTC seizure]).
To assess the association between anxiety and depression levels
(as measured by HADS) and HRQoL (as measured by QOLIE-31/P total
score), univariate linear regression analysis of the QOLIE-31/P total
score on anxiety and depression, respectively, was conducted and
Pearson's correlation coefﬁcients were calculated.
Univariate and stepwise multivariate logistic regression analyses
were undertaken to identify factors associated with poor HRQoL
(QOLIE-31/P total and EQ-5D-3L utility scores), using data from
patients in the PRO population who had completed the symptom
checklist. Poor HRQoL was deﬁned as having a QOLIE-31/P or EQ-5D-
3L score, respectively, in the lowest quartile. Initially, univariate
logistic regression was performed on a number of variables to identify
those to be included in the multivariate analyses (see Supplementary
Table 1). Variables assessed in the univariate analyses included the
following: sociodemographic characteristics (age, gender, body mass
index), disease characteristics (duration since diagnosis, type of
epilepsy syndrome), occurrence of seizures in the 4 weeks preceding
the assessment, severity of each symptom from the symptom check-
list, AED treatment ongoing at the time of assessment (monotherapy
or polytherapy; older AEDs [introduced before 1993] or newer AEDs
[introduced after 1993]), medication-related side effects perceived
by patients to be related to their treatment (recorded within the
4 weeks before assessment), and current comorbidities. Variables
were selected for inclusion if results from the univariate analysis
showed a p-value b 0.05. Results are presented as odds ratios with
95% conﬁdence intervals (CIs). Only variables with p b 0.05 are
presented. Factors highly predictive of poor HRQoL were deﬁned as
those with an odds ratio of N2 (positive predictor) or b0.5 (negative
predictor).
3. Results
3.1. Patient characteristics
The PatientsLikeMe population with epilepsy comprised 3073
users who registered and completed data online between January
2010 and November 2011. Of these, 69.5% were included in the
population with symptoms, and 36.5% completed all three PROquestionnaires (QOLIE-31/P, HADS, and EQ-5D-3L) at least once and
comprised the PRO population (Table 1). Overall, 36.2% completed
both the predeﬁned symptom checklist and the PRO instruments. A
total of 20.8% of patients recorded ≥1 side effect that they perceived
as being related to their medication and were included in the popula-
tion with side effects (Table 1).
In the population with epilepsy, 71.5% of patients were female. The
mean (SD) age of patients in the population with epilepsy was 37.8
(12.7) years; 7.3%, 76.3%, and 16.4% of patients were aged 0–20 years,
21–50 years, and N50 years, respectively, with 96.4% aged ≥18 years.
The mean time since diagnosis was 17.7 (14.1) years (Table 1). In
total, 79.1% (2412/3049) of patients who recorded information about
their diagnosing and/or treating physician had been diagnosed
by a pediatric neurologist/neurologist, and 73.4% (2034/2770) were
currently managed by a pediatric neurologist/neurologist. Diagnostic
tests had been carried out on 99.2% (2953/2978) of patients, with the
most frequent being magnetic resonance imaging (88.3%; 2607/2953),
electroencephalography (85.6%; 2528/2953), and computed tomography
(71.8%; 2120/2953). Of the patients who recorded a comorbid condition
(n = 2271), more than half (53.9%) recorded at least one, most fre-
quently migraine (28.1%), anxiety disorder (17.6%), major depressive
disorder (13.9%), and hypertension (10.5%) (Table 1). Of the patients
who recorded anAED therapy (n=1773), similar proportions recorded
monotherapy (51.4%) and polytherapy (48.6%); the majority (56.4%)
were treated with newer AEDs only (as monotherapy or as part of a
combination therapy). Approximately half of the patients (51.3%;
1488/2900) did not drive, with 84.8% (1261/1487) of these patients
citing epilepsy as the reason for not driving.
Overall, the demographic characteristics of the different subpopula-
tions appeared similar to those of the populationwith epilepsy, with the
exception of the percentage of patients who recorded unknown seizure
types (24.7%, 9.2%, 0.6%, and 4.2% for the population with epilepsy,
population with symptoms, PRO population, and population with side
effects, respectively).
3.2. Symptoms and medication-related side effects
Of the patients in the population with symptoms (n= 2135), 87.5%
recorded at least onemoderate or severe symptom from the predeﬁned
symptom checklist (36.2%: 1–3, 35.9%: 4–6, and 15.4%: 7–9). Symptoms
most frequently recorded as moderate or severe were memory
problems (60.2%), problems concentrating (53.8%), fatigue (50.0%),
and excessive daytime sleepiness (somnolence: 41.4%) (Fig. 1).
Among the patients who recorded medication-related side effects
that they perceived to be associated with their treatment (20.8% of
the overall population with epilepsy), 6.7% (43/639) recorded one,
28.3% (181/639) recorded two, and 64.9% (415/639) recorded three or
more medication-related side effects. The most frequently reported
medication-related side effects (in ≥10% of patients) were somnolence
(23.2%), fatigue (17.2%), memory impairment (13.8%), dizziness
(11.6%), and abnormal weight gain (10.5%).
3.3. HRQoL
In the PROpopulation, overallmean (SD) QOLIE-31/P total scorewas
51.5 (19.0), indicating a moderate level of HRQoL. The occurrence of
seizures during the 4 weeks preceding the QOLIE-31/P assessment
was found to negatively affect HRQoL across all domains (Fig. 2).
Patients recording ≥1 non-GTC seizure had signiﬁcantly worse
QOLIE-31/P scores, compared with those not recording any seizures.
These ﬁndings were more pronounced among patients experiencing
≥1 GTC seizure during the 4 weeks preceding QOLIE-31/P assessment.
Seizures affected all QOLIE-31/P domains in a similar manner for those
experiencing either a GTC or non-GTC seizure within the past 4 weeks
versus those who did not experience seizures. The greatest impact of
Table 1
Baseline demographic and epilepsy characteristics.
Parametera Population with epilepsy
(n = 3073)
Subpopulation
Population with symptoms
(n = 2135)
PRO population
(n = 1121)
Population with side effects
(n = 639)
Gender, n 2929 2107 1121 639
Female, % 71.5 73.2 72.2 73.4
Age, n 2909 2095 1120 633
Mean (SD), years 37.8 (12.7) 37.6 (12.6) 37.8 (12.3) 38.6
Age class, n 2909 2095 1120 633
0–20 years, n (%) 212 (7.3) 148 (7.1) 69 (6.2) 27 (4.3)
21–50 years, n (%) 2219 (76.3) 1608 (76.8) 869 (77.6) 491 (77.6)
N50 years, n (%) 478 (16.4) 339 (16.2) 182 (16.3) 115 (18.2)
Geographic location, n 2803 2070 1120 630
USA, n (%) 2757 (98.4) 2038 (98.5) 1120 (98.7) 620 (98.4)
Time since diagnosis, n 3044 2130 1121 637
Mean (SD), years 17.7 (14.1) 17.4 (13.8) 17.8 (13.7) 16.7 (13.3)
Age at ﬁrst seizure, n 2906 2095 1121 633
Mean (SD), years 17.2 (13.5) 17.1 (13.3) 16.5 (13.0) 17.8 (13.4)
Seizure type, n 3073 2135 1121 639
Generalized, n (%) 727 (23.7) 604 (28.3) 344 (30.7) 178 (27.9)
Partial, n (%) 729 (23.7) 621 (29.1) 376 (33.5) 202(31.6)
Mixed, n (%) 859 (28.0) 713 (33.4) 394 (35.1) 232 (36.3)
Unknown, n (%) 758 (24.7) 197 (9.2) 7 (0.6) 27 (4.2)
AED treatmentb,c, n 1773 1593 1121 594
Monotherapy, n (%) 912 (51.4) 802 (50.3) 484 (47.6) 288 (48.5)
Polytherapy, n (%) 861 (48.6) 791 (49.7) 533 (52.4) 306 (51.5)
Newer AEDs onlyd, n (%) 1000 (56.4) 899 (56.4) 570 (56.0) 333 (56.1)
Older AEDs onlyd, n (%) 351 (19.8) 309 (19.4) 183 (18.0) 158 (26.6)
Combination of newer and older AEDs, n (%) 422 (23.8) 385 (24.2) 264 (26.0) 103 (17.3)
Comorbiditiese, n 2271 1769 986 538
Patients with ≥1 comorbid condition, n (%) 1224 (53.9) 970 (54.8) 549 (55.7) 301 (55.9)
Migraine, n (%) 638 (28.1) 506 (28.6) 280 (28.4) 145 (27.0)
Anxiety disorder, n (%) 400 (17.6) 316 (17.9) 178 (18.1) 107 (19.9)
Major depressive disorder, n (%) 316 (13.9) 259 (14.6) 152 (15.4) 87 (16.2)
Hypertension, n (%) 239 (10.5) 190 (10.7) 112 (11.4) 59 (11.0)
AED, antiepileptic drug; PRO, patient-reported outcome; SD, standard deviation.
a Not all parameters were completed by all patients.
b Patients recorded ≥1 AED treatment.
c Members of the PatientsLikeMe Epilepsy Community who do not self-report AED treatment may take no AED(s) or may have not reported their treatment.
d Older AEDs include the following: acetazolamide, benzodiazepines, carbamazepine, ethosuximide,methsuximide, phenobarbital, phenytoin, sulthiame, and valproic acid. NewerAEDs
include the following: felbamate, gabapentin, lacosamide, levetiracetam, lamotrigine, oxcarbazepine, pregabalin, ruﬁnamide, retigabine, tiagabine, topiramate, vigabatrin, and zonisamide.
e Comorbidities recorded by ≥10% of the patients from a preset comorbidity checklist are reported.
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In the PRO population, the mean (SD) total EQ-5D-3L utility score
was 0.75 (0.20), which reﬂects a moderately impaired HRQoL. Slightly
lower mean EQ-5D-3L utility scores were seen in patients experiencing
≥1 non-GTC seizure (0.73 [0.20]; p b 0.001; n= 429) or ≥1 GTC seizure
(0.70 [0.21]; p b 0.001; n = 124) than in those not reporting seizures
(0.78 [0.19]; n = 568) during the 4 weeks preceding the assessment.Fig. 1.Distribution andmean symptom severity ratings atﬁrst evaluation for patientswho
completed the predeﬁned symptom checklist (population with symptoms; n = 2135).3.4. Anxiety and depression
Overall mean (SD) HADS scores were 9.5 (4.2) for anxiety and
6.9 (4.3) for depression, with 36.5% (409/1121) of patients reporting a
moderate or severe level of anxiety and 20.2% (226/1121) reporting a
moderate or severe level of depression. Overall, 157 of the 266 (59.0%)Fig. 2.Mean (SD) QOLIE-31/P scores by seizure status during the 4 weeks preceding the
assessment (PRO population, n = 1121).
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moderate or severe anxiety, while 157 of the 409 (38.4%) patients with
moderate or severe anxiety also had moderate or severe depression.
3.5. Correlation between HADS and QOLIE-31/P
Linear regression analyses, evaluating the association between
anxiety or depression (HADS) scores and HRQoL (QOLIE-31/P total
score), showed clear negative correlations (anxiety: r = −0.62;
depression: r =−0.69) (Fig. 3), suggesting that the presence of anxiety
and depression in this population, and their severity, negatively
inﬂuenced HRQoL.
3.6. Predictors of poor HRQoL
In patients from the PRO population who had also completed the
symptom checklist (n = 1113), 25.1% (279/1113) were classiﬁed as
having poor HRQoL, based on a QOLIE-31/P total score inferior to the
quartile 1 (Q1) score of 37.3. Based on an EQ-5D-3L utility score inferior
to the Q1 score of 0.71, 23.6% (263/1113)were classiﬁed as having poor
HRQoL.
Factors most predictive of poor HRQoL (odds ratio N2 or b0.5;
p b 0.05) differed according to the PRO instrument evaluated (Fig. 4A
and B). For epilepsy-speciﬁc HRQoL (measured by QOLIE-31/P), the
most predictive factors of poor HRQoL were as follows: moderate/
severe problems concentrating, occurrence of ≥1 GTC seizure during
the4weeks preceding thePRO assessment,moderate/severe depression,
epilepsy duration ≤1 year, moderate/severe memory problems, and
moderate/severe side effects during the 4 weeks preceding PRO assess-
ment (Fig. 4A). Additionally, patients not recording any AED treatment
or those on newer AEDs (monotherapy or polytherapy) were similarly
less likely to report poor HRQoL, compared with patients receiving
polytherapy with older AEDs exclusively. For the generic HRQoL assess-
ment measured using the EQ-5D-3L, the most predictive factors (odds
ratio N2) of poor health status were as follows: moderate/severe pain,
moderate/severe depression, ≥1 comorbidity, and comorbidity data
missing (Fig. 4B).
4. Discussion
This retrospective analysis of data from the PatientsLikeMe Epilepsy
Community provides valuable real-world data on epilepsy, its
treatment, and overall impact on patients' lives for a large population
of online community users. The demographic characteristics suggested
that the PatientsLikeMe Epilepsy Community was not representative
of the general population with epilepsy [5,19–21]. The PatientsLikeMe
Epilepsy Community had a greater proportion of female patientsFig. 3. Correlation between QOLIE-31/P total score and HADS anxiety and depression sc(71.5%) compared with data from the U.S. 2005 National Health
Interview Survey in adults with epilepsy (55.9%; [19]) and with
PharMetrics (53.6%; a claims database representative of the U.S.
commercially insured population, November–December 2008 [22]). In
addition, comparison with data from PharMetrics showed that the
PatientsLikeMe Epilepsy Community had a greater proportion of
patients aged between 21 and 50 years (76.3% vs. 44.2%) and patients
receiving AED polytherapy (48.6% vs. 28.7%) [22]. These differences
are indicative of biases compared with the general population with
epilepsy as a whole. Gender and age differences can have implications
on patients' perception of their disease, the comorbidities they suffer,
the AEDs they use, and their general well-being. For example, in the
population with epilepsy, depression is more commonly associated
with females thanmales [23], and a signiﬁcant age-by-gender interaction
for major depressive disorder has been reported [24]. These differences
could result in gender-speciﬁc preponderance on certain assessments
and further indicate that members from the PatientsLikeMe Epilepsy
Community may not be fully representative of the population with
epilepsy as a whole. The age and gender characteristics of the
PatientsLikeMe Epilepsy Community population are generally reﬂecting
the characteristics of online users of health forums willing to share
personal data [25,26]. However, it is interesting to mention that the
most frequently recorded comorbidities, moderate or severe symptoms,
and medication-related side effects patients perceived to be related to
their treatment in this PatientsLikeMe community were similar to those
reported in other studies in patients with epilepsy [5,27].
Patients with epilepsy are at an increased risk of medical comorbid-
ities. In total, 53.9% of patients recorded at least one comorbid condition,
similar to recent ﬁndings based on multiple health plans across the
United States, in which 58% of patients with epilepsy had one or more
of 29 prespeciﬁed comorbidities [28]. The proportions of patients
recording migraine (28.1%), anxiety disorder (17.6%), and major
depressive disorder (13.9%) as a comorbidity were within estimated
prevalence ranges reported for patients with epilepsy: migraine, 1.7–
33.6% [29]; anxiety, 15–20% [30]; depression, 4.1–32.5% [31]; and overall,
13.0% [31]. Comorbidities complicate treatment in general and, in
particular, treatment adherence in epilepsy. Pharmacological treatments
for other conditions and AEDs can result in drug–drug interactionswhich
in turnmay affect the treatment efﬁcacy/tolerability proﬁle. Additionally,
common psychological comorbidities such as depression and anxiety can
have considerable effects on a patient's quality of life [32].
Of the large proportion of patients who completed the predeﬁned
symptom checklist (69.5%), the vast majority (87.5%) recorded at least
onemoderate or severe symptom.Moreover, 20.8% of patients recorded
medication-related side effects that they associated with their treat-
ment. The predeﬁned symptom checklist and the side effects screen
record different yet complementary information. The symptom checklistores (n = 1113; PRO population who had also completed the symptom checklist).
Fig. 4. Factors associated with poor health-related quality of life (p b 0.05) by multivariate logistic regression analysis. Predictors (odds ratio N2 or b0.5; p b 0.05, as indicated by dotted
lines) of low QOLIE-31/P total score (bQ1)a (A) and low EQ-5D-3L utility score (bQ1)b (B) in the PRO population who had also completed the symptom checklist (n = 1113).
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systematic and standardized way (whether related to the disease, to co-
morbid conditions, or to medication-related side effects), while the side-
effect reporting system allows patients to record side effects they perceive
to be associated with a medication. It is important to note that it may be
difﬁcult for patients or their caregivers to differentiate symptoms
attributable to the disease from side effects resulting from the patient'smedication. Furthermore, spontaneous reporting of medication-related
side effects is subjective [33], while the use of standardized tools to record
symptoms allows for the collection of ‘complaints’ data from all patients.
Although both approaches have their limitations, it is interesting that
the two tools provided a similar pattern of reported complaints, with
cognitive problems, somnolence, and fatigue being the most frequent.
This is consistent with data from the U.S. 2010 National Health Interview
26 C. de la Loge et al. / Epilepsy & Behavior 63 (2016) 20–28Survey suggesting that individuals with epilepsy are more likely to report
cognitive limitations andmoderate or severe fatigue comparedwith those
without epilepsy [34] and is also consistent with data reported by other
sources [5,33,35–37].
Data from this retrospective analysis provide insight into the
different factors impacting patients' HRQoL. The mean QOLIE-31/P
total score (51.5) and EQ-5D-3L utility score (0.75) are indicative of a
patient population with a moderately impaired HRQoL.
It is well-documented that the occurrence of seizures substantially
reduces patient HRQoL [4,38]. This was replicated in our analysis,
particularly with the most severe type, GTC seizures. Depression and
anxiety have also been found to contribute to poor HRQoL in epilepsy
[21]. Previous results [38,39] from linear regression analyses indicate
clear negative correlations (r b−0.6) between anxiety and depression
scores and HRQoL, as measured by QOLIE-31/P, an association that
was conﬁrmed in the present multivariate, logistic regression analysis.
The multivariate analysis identiﬁed several additional factors
associated with poor HRQoL and showed that predictors of poor HRQoL
differed between the two measures (QOLIE-31/P and EQ-5D-3L). Gener-
alized tonic–clonic seizures occurring within the preceding 4 weeks,
epilepsy duration of ≤1 year, the presence of moderate or severe de-
pression, problems concentrating, andmemory problemswere all high-
ly predictive of poor HRQoL, as measured by QOLIE-31/P. Whereas, for
the EQ-5D-3L, the number of comorbidities (≥1) and moderate/severe
pain or depression were highly predictive of low HRQoL. The EQ-5D-
3L instrument includes moderate/severe pain/discomfort and moder-
ate/severe anxiety/depression as speciﬁc items within the measure;
thus, it is unsurprising that these factors appeared as predictive factors
for poor HRQoL in this assessment. Previous studies also found that
comorbidities, mood problems, the occurrence of seizures, and daily
functioning had a greater effect on HRQoL than short-term seizure
control [40,41]. The only highly predictive factor common to both PRO
measures was moderate/severe depression.
The disparities in predictive factors of poor HRQoL between the two
measures are likely the result of differences in the conceptual frame-
works of these measures, which cover different dimensions of patients'
HRQoL. Interestingly, the occurrence of seizures, the main outcome
considered by treating physicians and patients and by clinical trials,
was not associated with poor HRQoL measured by the EQ-5D-3L
instrument. In part, this could be explained by the different recall
periods of these two instruments and also illustrates the limitation of
using generic measures in the context of epilepsy. Limitations of the
EQ-5D-3L have been described elsewhere [42,43] and have led to the
development of the ﬁrst epilepsy-speciﬁc utility measure, the Quality
of Life in Newly Diagnosed Epilepsy Instrument—6D (NEWQOL-6D)
[44,45], which covers HRQoL dimensions more relevant to epilepsy,
such asworry about seizures, depression and social functioning, memo-
ry problems, cognitive problems, control of condition, and perceived
stigma. Indeed, the dimensions covered by NEWQOL-6D were
each identiﬁed in this research as being relevant to patients with
epilepsy.
Contradictory data have been published on theHRQoL of patients on
newer and older AEDs (on monotherapy and polytherapy) [35,46,47].
The results from this multivariate analysis to identify predictive factors
of poor HRQoL indicate that a patient not recording AED treatment, or
those on newer AEDs (monotherapy or polytherapy), was less likely
to report poor HRQoL (QOLIE-31/P), compared with those on
polytherapy with older AEDs. However, these data must be interpreted
with caution, as different factors relating to individual patient proﬁles
and disease characteristics, and not necessarily to AED treatment itself,
could affect both the AED treatment regimen and the HRQoL outcome.
The concept of online tools for tracking epilepsy is not new, as
evidenced by systems including Epilepsy.com, SeizureTracker.com,
and numerous smartphone apps. Increasingly, patients are being
encouraged to take an active role in the management of their disease,
and online communities have the potential to provide an easilyaccessible platform and tools for this purpose. Recording symptom and
medication-related side-effect information in a standardized way and
sharing it with a physician, for instance by printing out information or in-
viting the physician to view their proﬁle electronically, may help support
informed treatment decisions by highlighting issues previously unknown
to the physician, who in turn could adjust the healthcare provided in
view of improving outcomes, as described in previous observational
studies [5,33]. Indeed, one of the perceived beneﬁts of PatientsLikeMe
has been identiﬁed as better healthcare, as a result of recording
symptoms [11]. With the current number of PatientsLikeMe Epilepsy
Community users nearing 10,000, the perceived beneﬁts and support
network such an online platform could potentially offer to patients with
epilepsy are extremely encouraging.
A limitation of this analysis is the different recall periods each of
the PRO instruments request respondents to consider when answering
the questions. Therefore, conclusions and correlations drawn by
comparing data from the QOLIE-31 assessment (4-week recall period),
the EQ-5D-3L (day of assessment), and the HADS instrument (1-week
recall period) should be undertaken with caution.
Further limitations are related to the cross-sectional nature of this
analysis and the reliability and robustness of self-reported data. Such
data may be considered subjective, as they are dependent on the
patients' own perception of their disease, and of questionable reliability,
as they are not validated by a healthcare practitioner. Furthermore, the
requirement for internet access and sufﬁcient patient competency to
engage with such systems (previously shown to be lower in patients
with chronic disease) [48] should be considered. Moreover, participation
biasmay arise in those patientswho aremore likely to complete a certain
assessment or record their side effects. The ‘1% rule’, which states that,
within internet communities, 90% of members observe and do not
participate, 9% of members contribute sparingly, and 1% of members
create the vast majority of new content, has been observed within four
digital health social networks [49]. That being said, analysis of the data
from the PatientsLikeMe Epilepsy Community suggested substantial
involvement of its members in completing the different assessments at
least once (69% completed the symptoms checklist, 36% completed the
PRO instruments, and 21% recorded medication-related side effects).
Additionally, as it was not mandatory for patients to complete all the
information, sample sizes for each parameter were somewhat variable,
and thus, the sample size for multivariate analyses was smaller, which
may be a limitation of the open nature of the platform itself. Although
the PatientsLikeMe Epilepsy Community may not represent the overall
population with epilepsy, this is the case for a large number of data
sources used for research purposes.
Knowing these limitations, it is interesting to see that these results
are consistent with ﬁndings from studies in patients with epilepsy
using other methods of data collection [5,7,20,27,28,38,50].
4.1. Conclusions
Overall, our ﬁndings support the feasibility and usefulness of using
anonymized disease-related data recorded by patients on online
platforms like PatientsLikeMe for research purposes; for instance,
longitudinal tracking of individual patient care or regular cross-
sectional assessments of predictors of poor HRQoL to assess changes in
treatment standards over time. Indeed, data captured on PatientsLikeMe
have been used in a number of research studies relevant to epilepsy [51].
However, it must be noted that, as a new source of information, the
validity, generalizability, and relevance to clinical decision-making are
yet to be established. The data presented provide a useful insight into
real-life patients with epilepsy, allowing for an in-depth understanding
of patients' experiences with their disease, and suggest that predictors
of poor HRQoL in patients with epilepsy are numerous and not limited
to the occurrence of seizures. The variety of factors identiﬁed that predict-
ed poor HRQoL conﬁrms that a holistic approach, not focused on seizure
control alone, should be considered when treating people with epilepsy.
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